INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Kirn David sold FDMT

Director, See Remarks · 4D Molecular Therapeutics, Inc. · Common Stock

Side
SELL
Value
$1.20M
Shares
114.7K
Price
$10.47
Executed
Jun 22, 2026
Disclosed
Jun 23, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jun 22 executedJun 23, 2026 disclosed

FDMT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
23/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+14 / 25

    $1.2M reported value · 10.9% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · FDMT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    BS
    Bizily ScottChief Legal Officer
    FDMT4D Molecular Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$41K
    9,810 sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    25
    BS
    Bizily ScottChief Legal Officer
    FDMT4D Molecular Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$118K
    9,810 sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    3
    BS
    Bizily ScottChief Legal Officer
    FDMT4D Molecular Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    9,810 sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001834021-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 22, 2026
    Published
    Jun 23, 2026
    Ingested by INSIDER
    Nov 5, 03:51 UTC
    Last re-read
    Nov 5, 03:51 UTC

    Extracted facts

    Filer
    Kirn David
    Role
    Director, See Remarks
    Transaction
    Open-market saleAs filed: “S”
    Asset
    4D Molecular Therapeutics, Inc.
    Ticker
    FDMT
    Shares
    114.7K
    Price per share
    $10.47
    Value
    $1,200,851
    Execution date (reported)
    Jun 22, 2026
    Owned after transaction
    942.5K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 114.7K
    • Price: $10.4653

    = $1,200,851

    What this establishes

    Kirn David filed this Form 4 reporting a open-market sale of FDMT on Jun 22, 2026. It became public on Jun 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, See Remarks
    Kirn Davidcik:0001834021
    Issuer
    4D Molecular Therapeutics, Inc.cik:0001650648

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.